Figure 1
Summary of study design, including dose-escalation phase and eligibility criteria for the 4 expansion cohorts. IMiD, immunomodulatory drug; PD, progressive disease.
Summary of study design, including dose-escalation phase and eligibility criteria for the 4 expansion cohorts. IMiD, immunomodulatory drug; PD, progressive disease.
